The British Journal of Clinical Pharmacy
— Volume 1, Issue 8, September 2009
To download the complete issue, please select one of the following formats:
              
sept09_cover.jpg
Several new studies likely to impact cardiology practice in the near future were presented at this year’s European Society of Cardiology congress. Sotiris Antoniou describes the key findings.
Tredaptive (nicotinic acid and laropiprant; MSD) has recently been launched in the UK following European approval for the treatment of dyslipidaemia and primary hypercholesterolaemia. Mojgan Sani describes how this new formulation may improve compliance.
Pharmacokinetic differences between the three extended release preparations of methylphenidate lead to variations in release profiles and thus administration regimens. This article highlights the key points that pharmacists should be aware of. By Vanessa Redmond.
Dabigatran etexilate and rivaroxaban were both licensed recently for thromboprophylaxis following hip or knee surgery. In this article, the North Central London Formulary and Medicines Management Group review the evidence for the efficacy and safety of both drugs. By Anthony Grosso, Carolyn Gates and Pritesh Bodalia.
A growing number of clinical trials are being designed as non-inferiority studies. However, vigilance is needed to determine the clinical appropriateness of the margin of non-inferiority used in these studies. By Anthony Grosso.
Prescriber’s Corner describes situations encountered by pharmacist prescribers and invites you to consider clinical decisions about the patient. In this case, you must provide support to a patient diagnosed with pulmonary fibrosis following two years of methotrexate therapy. By Andrew Husband and Judith Heed.
Pharmacy needs innovation to get it through financial hardships, attendees at this year’s British Pharmaceutical Conference were told. Hannah Pike and Shona Kirk report.
Carol Paton is joint clinical lead at the prescribing observatory for mental health (POMH), a unique organisation that allows participating trusts to benchmark their quality of practice against national data. This article describes Mrs Paton’s role at POMH and elsewhere. By Shona Kirk.
Last year a pharmacist independent prescribing service was introduced in the acute medical unit at Hammersmith Hospital, London. Kandarp Thakkar and Binita Jani describe the implementation and evaluation of this service.
Now that the new professional leadership body has received the green light, the real battle for members begins. This will involve addressing the issues that really matter to both pharmacists and patients, starting with the safety of medicines, says Philip Brown.